Medtronic Shares Rise Following Strong Fiscal Q4 Earnings Beat

Medtronic (NYSE: MDT) saw its stock price climb 5.3% following the release of its fiscal fourth-quarter 2026 earnings report. The medical technology giant exceeded analyst expectations, reporting earnings of $1.55 per share against a consensus estimate of $1.54, while revenue reached $9.8 billion, surpassing the projected $9.6 billion. This performance marked a significant finish to the fiscal year, characterized by the company's strongest annual revenue growth in a decade.

The quarterly results highlighted a notable acceleration in momentum. Medtronic achieved a 9.9% year-over-year increase in sales, bolstered by both organic growth and strategic acquisitions. Furthermore, the company reported a 17% increase in GAAP earnings, a figure that significantly outpaced its top-line growth. While full-year earnings growth was more modest at 3.3%, the sharp uptick in the final quarter suggests the company is successfully scaling its operational efficiency.

Looking ahead, Medtronic has provided a positive outlook for fiscal 2027, projecting organic sales growth of approximately 7% and non-GAAP earnings between $5.90 and $6.00 per share. This guidance implies a potential doubling of income growth compared to the previous fiscal year. While some market observers remain cautious regarding the company's valuation relative to its growth rate, the combination of accelerating performance and a 3.8% dividend yield continues to attract investor interest, positioning Medtronic as a resilient player in the medical device sector.